Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

cidofovir injection

- PMLiVE

Gilead recalls Vistide due to foreign particles

Affected batch of AIDS symptom treatment sold in the US, Europe and Canada

- PMLiVE

Gilead $1bn antibody deal with MacroGenics

Joins Boehringer and Servier in use of US biotech’s DART technology

- PMLiVE

Gilead expands in cancer with $510m YM BioSciences deal

Lands JAK inhibitor CYT387

- PMLiVE

Streaming Well and Terrence Higgins Trust launch HIV education series

Online videos target young people in Britain

- PMLiVE

Efforts to curb HIV must be stepped up, says report

HIV/AIDS advocacy group ONE pushes for more funding to end epidemic

- PMLiVE

Gilead posts strong data for all-oral hepatitis C treatment

Achieves sustained virologic response in 78 per cent of participants

- PMLiVE

Access to AIDS treatment up by two thirds as countries increase investment

UNAIDS report says 8 million people in developing nations are now receiving antiretroviral therapy

- PMLiVE

Former PEPFAR head Mark Dybul to lead the Global Fund

Joins at time of change for the AIDS, tuberculosis and malaria focused non-profit organisation

- PMLiVE

Global Fund sacks inspector general, moves to new funding model

Also brings in former US global AIDS coordinator Mark Dybul as executive director

- PMLiVE

Gilead advances HIV drug into phase III

The treatment is a chemical variant of Gilead's successful HIV drug Viread

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links